Christof Vulsteke
Oncology — AZ Maria Middelares, Belgium
Christof Vulsteke
LeadR Profile
Oncology
Subspecialties: Urology - Gynecology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 135
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. research design, progression-free survival, ovary, neutropenia, neoplasms, bevacizumab, drug therapy, maintenance, drug-related side effects and adverse reactions, ovarian neoplasms, response evaluation criteria in solid tumors, therapeutics, carcinoma, ovarian epithelial, chemotherapy | Lancet Oncol Top journal | 2026 | 0 |
| Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply. urinary bladder, urinary bladder neoplasms, neoplasms | N Engl J Med Top journal | 2026 | 0 |
| TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer. proteinuria, neoplasms, thyroid gland, nephrotic syndrome, thyroid neoplasms, therapeutics | Acta Clin Belg | 2026 | 0 |
| PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. genes, recombination, genetic, homologous recombination, progression-free survival, anemia, androgens, neoplasms, prostate, drug-related side effects and adverse reactions, recombinational dna repair, prostatic neoplasms | N Engl J Med Top journal | 2026 | 0 |
| Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer. clinical protocols, urology, neoplasms, prostate, biomarkers, hormones, prostatic neoplasms, therapeutics | Eur Urol Focus | 2026 | 0 |
Clinical Studies 34
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK 2870 021) 2023-508047-40-00 — ovary, neoplasms, bevacizumab, drug therapy, maintenance, ovarian neoplasms, therapeutics, chemotherapy | Phase 3 | Recruiting | 2026 |
| A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK 2870 033) 2024-519331-42-00 — dna mismatch repair, safety, neoplasms, maintenance, respect, therapeutics, endometrial neoplasms, carcinoma | Phase 3 | Recruiting | 2025 |
| Pasritamig vs Placebo in late line Metastatic Castration resistant Prostate Cancer (mCRPC) 2025-520927-26-00 — cells, kallikreins, neoplasms, prostate, prostatic neoplasms, castration, t-lymphocytes | Phase 3 | Recruiting | 2025 |
| A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK 2870 031) 2024-520014-22-00 — neoplasms, drug therapy, chemotherapy, carcinoma | Phase 3 | Recruiting | 2026 |
| A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First Line Treatment of HER2 Expressing (IHC 3 2 ) Mismatch Repair Proficient (pMMR) Endometrial Cancer 2023-508056-19-00 — dna mismatch repair, neoplasms, drug therapy, therapeutics, trastuzumab, endometrial neoplasms, chemotherapy | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map